Lacipil (Lacidipine)

Lacidipine blocks L-type calcium channels in the smooth muscle of blood vessels. This inhibition prevents calcium‑mediated contraction, leading to vasodilation and a decrease in peripheral vascular resistance, which lowers systemic blood pressure.

The appropriate dose of Lacipil is determined by the prescribing healthcare professional based on the patient’s clinical condition, response to therapy, and any concomitant medications. Dosage adjustments are made individually.

Safety data for lacidipine in pregnancy and lactation are limited. It should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare provider.

To order Lacipil, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

Lacipil belongs to the calcium channel blocker class, which primarily causes vasodilation. Compared with ACE inhibitors or beta‑blockers, it may have a different side‑effect profile, such as a lower incidence of cough but a higher chance of peripheral edema. Choice of therapy depends on patient‑specific factors and physician judgment.

Lacipil tablets should be stored at room temperature, below 25 °C, in the original container to protect them from moisture and light. Keep the product out of reach of children and do not use after the expiry date.

Lacipil is taken orally, usually once daily with or without food, as directed by the prescribing clinician. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include severe hypotension, which can cause fainting or shock, and rare events such as angioedema, hepatic dysfunction, and cardiac arrhythmias. Patients should seek immediate medical attention if they experience swelling of the face or throat, sudden weakness, or irregular heartbeats.

Lacipil is contraindicated in patients with known hypersensitivity to lacidipine or any component of the formulation, and it should be used with caution in individuals with severe liver disease, unstable angina, or those taking strong CYP3A4 inhibitors. A healthcare professional should evaluate suitability before initiation.